Drappa Jorn 4

What Happened

• Drappa Jorn, Chief Medical Officer of Alumis, received a derivative equity award covering 221,450 shares on 2026-01-26. The award has an acquisition price of $0.00 (no cash paid at grant) and is reported as a grant/award (Form 4 transaction code A). This is a grant of an equity-based instrument, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-26; Form 4 filed: 2026-01-28 (timely filing).
• Award size: 221,450 shares (derivative award); acquisition price reported $0.00 (no immediate cash value recorded).
• Shares owned after transaction: Not specified in the filing.
• Vesting: 25% vests on January 26, 2027; remaining shares vest in equal monthly installments over the following 36 months, subject to continuous service and possible acceleration per the Issuer's 2024 Equity Incentive Plan (footnote).
• Filing timeliness: Filing appears timely (within the Form 4 reporting window).

Context

• This is an equity award (derivative grant) subject to multi-year vesting. There were no shares sold or exercised in this filing, and no immediate cash proceeds. Such grants are typically part of executive compensation and do not by themselves signal a buy or sell decision.